Stevanato Group S.p.A.
STVN
Positions held
Your positionsSTVN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Stevanato Group operates in the growing healthcare sector, specifically in medical instruments and supplies, which is expected to see increased demand due to an aging population and rising healthcare needs.
- In the latest quarter, Stevanato reported a revenue increase of 10% compared to the prior quarter, reaching $302 million.
- The company's gross margin improved to 28.7%, up from 27.5% in the previous quarter.
- Despite the growth in revenue, Stevanato's earnings have shown a decline, with a year-over-year earnings growth rate of -26.5%.
- The company's operating margin has fluctuated, with a decrease to 16.98% in the most recent quarter from 20.23% in the previous quarter.
- Stevanato's free cash flow is negative at -$104.7 million, indicating potential liquidity issues.
Fundamentals
| Market cap | $5.25B | Enterprise value | $5.61B | Trailing P/E | 33.70 | Forward P/E | 23.02 |
| PEG | 1.40 | Price / book | 3.01 | Beta | 0.78 | Dividend yield | 0.32% |
| Revenue growth | 7.8% | Earnings growth | -26.5% | Gross margin | 29.4% | Operating margin | 17.2% |
| Profit margin | 11.0% | ROE | 9.1% | ROA | 5.4% | Debt / equity | 0.29 |
| Current ratio | 1.61 | Free cash flow | -$104.70M | Analyst recommendation | buy | Mean target | $24.47 |
| 52w high | $27.99 | 52w low | $12.89 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $302M | $274M | $346M | $303M | $280M | — |
| Op margin | 17.0% | 14.2% | 20.2% | 17.4% | 14.8% | — |
| Net income | $23.0M | $28.0M | $47.6M | $36.1M | $29.7M | — |
| Gross margin | 28.7% | 27.5% | 30.9% | 29.2% | 28.1% | — |
| Gross profit | $86.8M | $75.2M | $107M | $88.5M | $78.6M | — |
| Operating income | $51.3M | $38.8M | $70.1M | $52.7M | $41.4M | — |
- Revenue +10% vs prior quarter ($302M vs $274M).
- Gross margin 28.7% (was 27.5% prior quarter).
- Operating margin expanded to 17%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.1B | $1.1B | $984M | — |
| Op margin | 16.8% | 14.6% | 18.5% | 19.6% | — |
| Net income | $140M | $118M | $146M | $143M | — |
| Gross margin | 29.0% | 27.4% | 31.3% | 32.5% | — |
| Gross profit | $344M | $302M | $340M | $320M | — |
| Operating income | $199M | $161M | $201M | $192M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Deutsche Bank Initiates Stevanato Group at Hold, $22 Price Target
2026-10-01 · Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American Injectables
2026-10-01 · United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?
2026-09-18 · electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar?
2026-09-09 · UBS Adjusts Price Target on Stevanato Group to $23 From $28, Keeps Neutral Rating
2026-09-08 · Stevanato Group to Participate in Two Upcoming Investor Conferences
2026-09-04 · Stevanato Group (STVN) Trades A Subsidiary For Margin Gains And Growth
2026-09-01 · Riverwater Sees a Market Overreaction in Stevanato Group (STVN) After Oral GLP-1 Launches
2026-08-11 · Stevanato Group (STVN) Could Be 16% Undervalued Following Earnings And Guidance Update
2026-08-10 · How Investors Are Reacting To Stevanato Group (STVN) Trimmed Guidance And New GLP-1 Pen Approvals
2026-08-10 · Stevanato Group (STVN) Stock Looks Cheap On Cash Flow But Pricey On Earnings
2026-08-09 · Stevanato Group Q2 Earnings Call Highlights
Price (daily)
Full chart · RSI · MACD · patterns